The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life
Whilst FOLFIRINOX achieves high initial disease control in advanced PDAC, its benefit is limited by substantial toxicity and poor durability. Only a minority of patients maintain disease control beyond 6 months, which is strongly associated with improved survival. These findings suggest a need to redefine 'valuable FOLFIRINOX chemotherapy' to encompass not only initial response but also sustained disease control, toxicity management, and shared decision-making to optimise the benefit of FOLFIRINOX for patients.
Authors
- Casper W.F. van Eijck (ORCID: https://orcid.org/0000-0002-1461-6725)
- Gaby J. Strijk (ORCID: https://orcid.org/0009-0008-8916-2300)
- Judith Rietjens (ORCID: https://orcid.org/0000-0002-0538-5603)
- Aniek E. van Diepen (ORCID: https://orcid.org/0009-0007-0192-5354)
- J. de Vos-Geelen
- Brigitte C. M. Haberkorn
- Johanna W. Wilmink
- Anne M. Stiggelbout
- Casper H. J. van Eijck
- Marjolein Y. V. Homs
Institutions
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Erasmus MC (NL)
- Maasstad Ziekenhuis (NL)
- Maastro Clinic (NL)
- Erasmus University Rotterdam (NL)
- Delft University of Technology (NL)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1007/s00520-026-10568-3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00